9 februari 2020: lees ook dit artikel:
9 februari 2020: wellicht is deze meta-analyse interessant eens te raadplegen: Efficacy and safety of osimertinib in treating EGFR‐mutated advanced NSCLC: A meta‐analysis
Abstract staat onderaan artikel:
13 augustus 2018: Bron: JAMA Oncol. Published online August 2, 2018
Osimertinib is een zogeheten EGFR medicijn, een gericht medicijn (targeted therapy), gericht met...
Men with localized prostate cancer were randomized to radical prostatectomy or observation to compare nonfatal health outcomes and long-term mortality. After 19.5 years of follow-up, the overall mortality rate and the disease-specific mortality rate were not significantly different between the two groups. Among men...